tumour infiltrating lymphocytes - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Can Iovance Biotherapeutics TILt the balance in favour of approval?

tumour infiltrating lymphocytes
Patients who progress on either PD-1 or BRAF/MEK inhibitors are notoriously difficult to treat. Credit: David A Litman/Shutterstock.